News | June 17, 2014

CompanionDx Reference Lab And Rx Review Service, LLC Announce Partnership To Deliver Pharmacogenomics To Global Audience

HOUSTON--(BUSINESS WIRE)--

CompanionDx Reference Lab, a high-complexity CLIA certified laboratory specializing in pharmacogenomics, cancer companion diagnostics, targeted NGS and epigenomics testing, today announced that it has partnered with Rx Review Service, LLC. Rx Review Service is a hospital based pharmacy replenishment program administrator geared toward efficient medication distribution through all patient demographics. This partnership will expand markets and promote pharmacogenomic testing to a global audience.

“Recognizing the changing dynamics of healthcare through personalized medicine, CompanionDx Lab and Rx Review Service seek to increase availability of qualified and reliable pharmacogenomic testing to healthcare institutions and physician practices to better optimize patient therapy,” said Michael Stewart, CEO of CompanionDx Lab.

“The partnership provides an opportunity to grow and expand market presence, bringing the benefits of pharmacogenomic testing to the entire healthcare industry,” said Jerry Wanio, president of Rx Review Service. “We are excited about the advancement of personalized medicine and the goal toward safe and effective medication choices. We recognize that improved patient outcomes, reduced waste and increased cost savings to healthcare institutions, physicians and patients will be realized as a result of individualized dosages that specifically target an illness.”

About CompanionDx TM

With locations in Houston Texas and Honolulu, Hawaii, CompanionDx™ Reference Lab is a high-complexity CLIA certified laboratory specializing in pharmacogenomics, cancer companion diagnostics, targeted NGS and epigenomics testing. CompanionDx™ is committed to the next evolution in cancer care where comprehensive genetic data is delivered in an actionable format, thereby enabling the physician to make treatment decisions and choose healthcare strategies based on unique cancer type and the genetic makeup of each patient. CompanionDx™’s comprehensive and tumor-specific panels, coupled with personalized pharmacogenomic analysis, provide a unique offering that allows physicians to choose relevant and targeted therapies. For more information, visit www.companiondxlab.com.

About Rx Review, LLC

Rx Review, LLC headquartered in East Hanover, NJ acts as a liaison between client physicians, healthcare institutions and pharmaceutical manufacturers to replace pharmaceutical products and medical devices by utilizing all existing patient assistance programs. Acting independently, with a vested interest only for our clients and their patients, the service boasts proprietary software, EnrollNet, to digitally manage and track the entire process, including medications and devices for use at home.

For more information, visit www.rxreviewllc.com


Copyright Business Wire 2014

Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers